Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for chronic heart failure: a proof-of-concept randomized placebo-controlled study
2020-002864-30Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, randomised trial in heart failure with reduced ejection fraction (HFrEF) comparing Sulodexide with Placebo (2 arms). Primary endpoint: Percentage change in N-terminal pro-B-type natriuretic peptide (NT-proBNP). Started Jun 2020; status: terminated.
02
Drugs
sulodexide
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2020-002864-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002864-30.